INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (29)
2023
-
Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study
Frontiers in Cardiovascular Medicine, Vol. 10
-
Global disparities in patients with multiple myeloma: a rapid evidence assessment
Blood Cancer Journal, Vol. 13, Núm. 1
2022
-
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools
Value in Health, Vol. 25, Núm. 10, pp. 1760-1767
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282
-
Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Journal of Clinical Oncology, Vol. 37
-
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups
Prostate, Vol. 82, Núm. 13, pp. 1237-1247
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
European Journal of Cancer, Vol. 156, pp. 70-82
-
The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain
Mycoses, Vol. 64, Núm. 1, pp. 66-77
2020
-
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Leukemia, Vol. 34, Núm. 8, pp. 2125-2137
-
Disease features associated with a low disease impact in patients with psoriatic arthritis: Results of a cross-sectional multicenter study
Arthritis Research and Therapy, Vol. 22, Núm. 1
-
The economic burden of metastatic breast cancer in Spain
European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24
2019
-
Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis
Journal of Rheumatology, Vol. 46, Núm. 7, pp. 710-715
2018
-
Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases
Cell Death and Differentiation, Vol. 25, Núm. 3, pp. 542-572
2017
-
Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA®
Quality of Life Research, Vol. 26, Núm. 3, pp. 767-778
-
Minimal disease activity and impact of disease in psoriatic arthritis: A Spanish cross-sectional multicenter study
Arthritis Research and Therapy, Vol. 19, Núm. 1
2016
2015
-
Disability in bipolar i disorder: The 36-item World Health Organization Disability Assessment Schedule 2.0
Journal of Affective Disorders, Vol. 174, pp. 353-360